A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: LY3295668 Erbumine|DRUG: Endocrine therapy|DRUG: Midazolam
Sponsor: Eli Lilly and Company